SAN DIEGO, Feb. 6 /PRNewswire/ -- NovaCardia, a pharmaceutical company developing small molecule drugs for the treatment of cardiovascular diseases, announced today the appointment of Joseph L. Turner to the company's Board of Directors. Mr. Turner brings over 25 years of financial management experience in the pharmaceutical industry to the board of NovaCardia.
"Joe has played an integral role in the success of both privately held and publicly traded companies, having raised millions of dollars to support biopharmaceutical innovations and grown the companies he's worked with," said Randall E. Woods, President and CEO of NovaCardia. "We look forward to his counsel as the company achieves important company milestones this year, including the initiation of pivotal Phase III trials for KW-3902 for the treatment of congestive heart failure."
Until its sale to Gilead in November 2006, Mr. Turner was Senior Vice President of Finance and Administration and Chief Financial Officer at Myogen, a therapeutics company focused on cardiovascular disease. Prior to Myogen, he was at biopharmaceutical company Centaur Pharmaceuticals, where he served as Vice President, Finance and Chief Financial Officer. Before Centaur, Mr. Turner was Vice President, Finance and Chief Financial Officer of Cortech, Inc. and before that spent 12 years with Eli Lilly and Company, where he held a variety of financial management positions both within the United States and abroad.
NovaCardia is a privately held product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing novel, clinical-stage drug candidates. For more information, visit www.novacardia.com.
CONTACT: Brian Farmer, Director of Corporate Development of NovaCardia,+1-858-509-0455, bfarmer@NovaCardia.com; or Media & Investor Relations, KimRichards of Porter Novelli Life Sciences, +1-619-849-5377,firstname.lastname@example.org, for NovaCardia